SCHEMBL22433551

SCHEMBL22433551

CCN1CCC(N2CCC(S(=O)(=O)NC(=O)Nc3c(C(C)C)cc(Cl)cc3C(C)C)C2)CC1

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 2/20 0.41
▸ KMT2A Q03164 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22433555 0.91 RECQL (0.36) NLRP3
SCHEMBL22433568 0.90 NLRP3 (0.46) NLRP3ALDH1A1GAA
SCHEMBL24922411 0.89 — —
SCHEMBL22433571 0.85 NLRP3 (0.42) NLRP3KMT2A
SCHEMBL22433297 0.84 NLRP3 (0.47) NLRP3
SCHEMBL20636123 0.82 NLRP3 (0.45) NLRP3
SCHEMBL22433384 0.82 NLRP3 (0.45) NLRP3KMT2A
SCHEMBL20635811 0.82 NLRP3 (0.45) NLRP3
SCHEMBL20635809 0.81 NLRP3 (0.46) NLRP3
SCHEMBL24922447 0.81 RECQL (0.37) NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2023-02-02 — — US disclosed
US-20200291003-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2020-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291003-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 NLRP3 1/4885KMT2A 2805/4885ALDH1A1 754/4885
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 NLRP3 1/4885KMT2A 2774/4885ALDH1A1 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback